Effects of insulin-like growth factor-I and its analogue, long-R3-IGF-I, on intestinal absorption of 3-O-methyl-D-glucose are less pronounced than gut mucosal growth responses.

Garnaut SM, Howarth GS, Read LC

Growth factors (Chur, Switzerland)1 Mar 2002Cited by 2 (Europe PMC)

PMID11999215DOI10.1080/08977190290022194PepBankPUB-11999215

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, long-R3-IGF-I increased by 40% the initial rate of plasma appearance of the glucose analogue 3MG after the lower gavage dose.
In plain wordsIn rats, long-R3-IGF-I raised how fast a sugar analogue appeared in the blood by 40% after a low dose.
Peptide
IGF-1 LR3
Outcome
IncreaseInitial rate of 3MG appearance in plasma, lower 3MG dose
Study
ratn: not reported in source
Rats given IGF-I peptides for 7 days
Comparator
Vehicle
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated · subcutaneous mini-pump · 7 daysAs given in this study (rat).
Measurements
Initial rate of 3MG appearance in plasma
40%
lower 3MG dose
Source sentences
Summary
With the lower 3MG dose, only long-R3-IGF-I increased (40%) the initial rate of 3MG appearance in plasma.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats received vehicle, IGF-I or the more potent analogue, long-R3-IGF-I via subcutaneously implanted mini-pump, for 7 days, at which time intestinal absorption was assessed by: (1) plasma 3MG appearance following oral gavage, (2) single-pass- or (3) recirculating-perfusion of a jejunal segment.
Report a problemFND-1199921501
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, long-R3-IGF-I did not change the plasma appearance of 3MG after the higher gavage dose.
In plain wordsIn rats, long-R3-IGF-I did not change how fast a sugar analogue appeared in the blood after a high dose.
Peptide
IGF-1 LR3
Outcome
No significant changeInitial rate of 3MG appearance in plasma, higher 3MG dose
Study
ratn: not reported in source
Rats given IGF-I peptides for 7 days
Comparator
Vehicle
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated · subcutaneous mini-pump · 7 daysAs given in this study (rat).
Source sentences
Summary
IGF-I had no significant effect, whilst at the higher 3MG dose neither peptide was effective.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats received vehicle, IGF-I or the more potent analogue, long-R3-IGF-I via subcutaneously implanted mini-pump, for 7 days, at which time intestinal absorption was assessed by: (1) plasma 3MG appearance following oral gavage, (2) single-pass- or (3) recirculating-perfusion of a jejunal segment.
Report a problemFND-1199921502
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, jejunal perfusion showed that long-R3-IGF-I increased 3MG uptake per cm of jejunum by up to 69%.
In plain wordsIn rats, long-R3-IGF-I raised sugar analogue uptake per centimetre of gut by up to 69%.
Peptide
IGF-1 LR3
Outcome
Increase3MG uptake per cm of jejunum
Study
ratn: not reported in source
Rats given IGF-I peptides for 7 days
Comparator
Vehicle
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated · subcutaneous mini-pump · 7 daysAs given in this study (rat).
Measurements
3MG uptake per cm of jejunum increase
≤ 69%
long-R3-IGF-I
Source sentences
Summary
Utilising perfusion techniques, long-R3-IGF-I, but not IGF-I, significantly increased 3MG uptake per cm of jejunum by up to 69%, although significance was lost when expressed as a function of tissue weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats received vehicle, IGF-I or the more potent analogue, long-R3-IGF-I via subcutaneously implanted mini-pump, for 7 days, at which time intestinal absorption was assessed by: (1) plasma 3MG appearance following oral gavage, (2) single-pass- or (3) recirculating-perfusion of a jejunal segment.
Report a problemFND-1199921503
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, the increase in jejunal 3MG uptake with long-R3-IGF-I lost significance when expressed per tissue weight.
In plain wordsIn rats, the gut uptake gain with long-R3-IGF-I was no longer significant when measured per weight of tissue.
Peptide
IGF-1 LR3
Outcome
No significant change3MG uptake per tissue weight
Study
ratn: not reported in source
Rats given IGF-I peptides for 7 days
Comparator
Vehicle
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
Dose not stated · subcutaneous mini-pump · 7 daysAs given in this study (rat).
Source sentences
Summary
although significance was lost when expressed as a function of tissue weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats received vehicle, IGF-I or the more potent analogue, long-R3-IGF-I via subcutaneously implanted mini-pump, for 7 days, at which time intestinal absorption was assessed by: (1) plasma 3MG appearance following oral gavage, (2) single-pass- or (3) recirculating-perfusion of a jejunal segment.
Report a problemFND-1199921504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.